https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-30 06:03:032025-10-30 06:03:03Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-30 06:03:032025-10-30 06:03:03Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-29 17:13:252025-10-29 17:13:25Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
https://www.optimumcomms.com/wp-content/uploads/2023/09/WiLD_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-28 09:04:042025-10-28 09:04:04Women in Life Science Denmark (WiLD) expands mentoring program to support next generation of female leaders in life sciences
https://www.optimumcomms.com/wp-content/uploads/2025/02/Domain_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-28 08:40:512025-10-28 08:40:51Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors
https://www.optimumcomms.com/wp-content/uploads/2023/02/ViCentra_Logo_300x180px-3.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-28 08:30:232025-10-28 08:30:23ViCentra Strengthens Leadership Team to Accelerate Growth
https://www.optimumcomms.com/wp-content/uploads/2025/09/AMS.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-27 08:51:022025-10-27 08:51:02AMS to participate in upcoming investor conferences in November and December
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-23 08:59:002025-10-23 08:59:20Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 14:54:522025-10-21 14:54:52Novo Holdings to make changes to its Board of Directors
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 14:53:072025-10-21 14:53:07The Novo Nordisk Foundation proposes new candidates for election as members of the Board of Directors of Novo Nordisk A/S
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 14:31:382025-10-24 16:27:46Biocomposites launches SYNICEM™ spacers in the U.S.
https://www.optimumcomms.com/wp-content/uploads/2023/08/Astraveus.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 08:34:142025-10-21 08:34:14Astraveus further strengthens world class leadership team to advance development of Lakhesys Benchtop Cell Factory™
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 08:32:362025-10-21 08:32:36Novo Holdings co-leads €40m fundraising to scale MATR Foods’ production of organic plant-based meat alternatives
https://www.optimumcomms.com/wp-content/uploads/2025/10/Mission_Therapeutics_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-15 09:06:302025-10-15 09:06:30Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials
https://www.optimumcomms.com/wp-content/uploads/2025/07/Actithera-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-14 08:32:542025-10-14 08:32:54Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications
https://www.optimumcomms.com/wp-content/uploads/2025/01/Ona_Therapeutics_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-14 08:30:322025-10-14 08:33:36Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-10 09:12:332025-10-10 09:12:33Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAVWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
